Shanghai-based ABM Therapeutics, Inc. has announced the commencement of the first patient enrollment and dosing in a Phase I clinical study for its investigational drug ABM-168 in the United States. This open, dosage escalation, dosage expansion study, which received approval in the country in October 2022, is designed to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the drug in patients with advanced solid tumors.
ABM-168: A Promising MEK Inhibitor with High Selectivity and Solubility
ABM-168, an in-house developed small molecule MEK inhibitor, boasts high selectivity, high water solubility, and high blood-brain barrier permeability. MEK, a component of the MAPK pathway, is often activated in cancer and is highly expressed in various solid tumors, including those carrying RAS mutations. ABM-168 has demonstrated significant anticancer efficacy across a range of cancer cell lines and xenograft animal models, particularly in brain in situ models, indicating its potential in treating cancers that are challenging to address.
Implications for Advanced Solid Tumor Treatment
The Phase I study of ABM-168 represents a significant step forward in the development of targeted therapies for advanced solid tumors. If successful, this drug could offer a new treatment option for patients with limited therapeutic alternatives, potentially improving outcomes and quality of life.-Fineline Info & Tech
